2L
CBAY

22NW LP’s Cymabay Therapeutics CBAY Stock Holding History

22NW LP’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-295,676
Closed -$438K – 108
2020
Q1 		$438K Buy
+295,676
New +$496K 0.34% 90

Other funds holding CBAY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

22NW LP's CBAY Position: Q2 2020 in Review

22NW LP sold out of Cymabay Therapeutics (CBAY) in Q2 2020, closing a stake of 295,676 shares — an estimated $438K sold.

22NW LP first reported a position in CBAY in Q1 2020 and held it in 1 quarter. The position peaked at $438K in Q1 2020. 114 funds tracked by Wall St. Rank hold CBAY as of Q2 2020.

  • 22NW LP reported no remaining Cymabay Therapeutics position as of Q2 2020 after selling out during the quarter.
  • 22NW LP sold 295,676 Cymabay Therapeutics shares in Q2 2020, an estimated $438K.
  • 22NW LP first reported a position in Cymabay Therapeutics in Q1 2020 and held it in 1 quarter.
  • 22NW LP's Cymabay Therapeutics position peaked at $438K in Q1 2020.
  • 114 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2020.

Based on 22NW LP's 13F filing for Q2 2020, filed 14 Aug 2020.